Claudin 18 (CLDN18)
CLDN18 is a tight junction protein expressed in gastric and other epithelial tissues. Aberrant expression, particularly CLDN18.2, is a validated target for antibody-based therapies in gastric and gastroesophageal cancers.
Where this biomarker is used
Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.
Approvals where Claudin 18 (CLDN18) is defined directly in the indication labeling.
| Indication | Biomarker criteria | Therapies |
|---|---|---|
Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Solid Tumor · Stomach/GEJ |
|
Approvals defined at the solid tumor level where Claudin 18 (CLDN18) is part of the eligibility criteria.
No tumor-agnostic approvals are currently mapped for this biomarker.
Tests that measure this biomarker
These assays report Claudin 18 (CLDN18) as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.
Reports Claudin 18 (CLDN18) as part of its biomarker panel.